Tags : TOURMALINE-MM2

Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study

Tuba Khan March 11, 2020

Shots: The P-III TOURMALINE-MM2 study involves assessing of Ninlaro + lenalidomide + dexamethasone vs PBO + lenalidomide + dexamethasone in 705 transplant-ineligible patients with newly diagnosed MM The P-III TOURMALINE-MM2 […]readmore

Tags : TOURMALINE-MM2

Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : TOURMALINE-MM2

Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company